Provided by Tiger Trade Technology Pte. Ltd.

Ocular Therapeutix

10.35
+0.47504.81%
Volume:699.77K
Turnover:7.25M
Market Cap:2.26B
PE:-7.32
High:10.55
Open:10.09
Low:10.06
Close:9.87
52wk High:16.44
52wk Low:6.23
Shares:218.91M
Float Shares:185.00M
Volume Ratio:0.74
T/O Rate:0.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4140
EPS(LYR):-1.4203
ROE:-72.99%
ROA:-34.95%
PB:4.35
PE(LYR):-7.28

Loading ...

What Ocular Therapeutix (OCUL)'s SOL-X Long-Term AXPAXLI Extension Study Means For Shareholders

Simply Wall St.
·
May 02

Ocular Therapeutix announces annual shareholder meeting

Reuters
·
May 01

Ocular Therapeutix (OCUL) Receives a Buy from William Blair

TIPRANKS
·
Apr 29

Ocular Therapeutix enrolls first patient in Axpali trial

TIPRANKS
·
Apr 29

Ocular Therapeutix enrolls first patient in SOL-X AXPAXLI wet AMD extension trial

Reuters
·
Apr 29

Ocular Therapeutix™ Announces First Patient Enrolled in Sol-X Long-Term Extension Trial for Axpaxli™ in Wet Amd

THOMSON REUTERS
·
Apr 29

Ocular Therapeutix to report first-quarter results, host conference call and webcast

Reuters
·
Apr 28

Ocular Therapeutix to present at Bank of America Health Care Conference fireside chat

Reuters
·
Apr 27

Assessing Ocular Therapeutix (OCUL) Valuation As AXPAXLI Prospects Drive A Wide Gap To Fair Value Estimates

Simply Wall St.
·
Apr 22

Ocular Therapeutix to host investor day webcast

Reuters
·
Apr 22

Ocular Therapeutix grants inducement equity awards to new hires under 2019 plan

Reuters
·
Apr 14

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Apr 14

BUZZ-U.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune

Reuters
·
Apr 14

Ocular's Axpaxli Cuts Risk Of Worsening In Late-Stage AMD Study

Benzinga_recent_news
·
Apr 14

Ocular Therapeutix Price Target Maintained With a $21.00/Share by HC Wainwright & Co.

Dow Jones
·
Apr 14

BUZZ-U.S. STOCKS ON THE MOVE-Allogene Therapeutics, Adobe, Williams-Sonoma

Reuters
·
Apr 13

BUZZ-Ocular Therapeutix rises as new eye drug shows longer disease control

Reuters
·
Apr 13

Ocular Therapeutix posts positive week-52 data from SOL-1 Phase 3 AXPAXLI trial

Reuters
·
Apr 13

Ocular Therapeutix™ Announces Additional Positive Week 52 Data From Landmark Sol-1 Phase 3 Trial of Axpaxli™ in Wet Amd

THOMSON REUTERS
·
Apr 13

Ocular Therapeutix Inc - Axpaxli Meets Statistical Significance in Multiple Secondary Endpoints in Sol-1 Trial

THOMSON REUTERS
·
Apr 13